Brief: Biontech And Dualitybio Announce Topline Results Of Global Phase 3 Clinical Trial for Breast Cancer
Mon 09:08
BRIEF-Biontech And Dualitybio Announce Topline Results Of Global Phase 3 Clinical Trial for Breast Cancer Oct 26 (Reuters) - BIONTECH SE 22UAy.DE:
BIONTECH AND DUALITYBIO ANNOUNCE TOPLINE RESULTS OF THE DYNASTY-BREAST02 GLOBAL PHASE 3 CLINICAL TRIAL EVALUATING TRASTUZUMAB PAMIRTECAN IN HR+/HER2-LOW METASTATIC BREAST CANCER
TRASTUZUMAB PAMIRTECAN SHOWS MODEST PFS IMPROVEMENT VERSUS CHEMOTHERAPY IN HR+/HER2-LOW METASTATIC BREAST CANCER
INTERIM ANALYSIS FOR OVERALL SURVIVAL DATA NOT MATURE IN DYNASTY-BREAST02 TRIAL
HIGHER RATE OF INTERSTITIAL LUNG DISEASE REPORTED IN DYNASTY-BREAST02 TRIAL
Source text: ID:nGNE4nXmbY
Further company coverage: [22UAy.DE]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioNTech SE
See all newsBrief: Biontech And Dualitybio Announce Topline Results Of Global Phase 3 Clinical Trial for Breast Cancer
Brief: Biontech And Bristol Myers Squibb Report Encouraging Global Phase 2 Data For Pumitamig In Advanced Nsclc After Progression On Immunotherapy Plus Chemotherapy
BioNTech, Gilead to test drug combination in advanced breast cancer trial
Brief: BioNTech Starts Phase 3 Trial of Pumitamig Plus Gilead's Trodelvy for Breast Cancer
Brief: Biontech To Showcase Oncology Late-Stage Pipeline Progress At ESMO 2026